TRVI · Trevi Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $33.48M | $39.38M | $23.68M | $19.83M | $22.98M | $22.33M |
| SG&A | $15.85M | $12.15M | $10.24M | $10.07M | $9.49M | $10.16M |
| Total Operating Expenses | $49.33M | $51.52M | $33.92M | $29.91M | $32.48M | $32.49M |
| D&A | $144.0K | $147.0K | $123.0K | $43.0K | $50.0K | $47.0K |
| Operating Income | ($49.33M) | ($51.52M) | ($33.92M) | ($29.91M) | ($32.48M) | ($32.49M) |
| Interest Expense | $0 | $4.0K | $391.0K | $1.16M | $1.20M | $456.0K |
| Income Tax | ($64.0K) | ($30.0K) | ($32.0K) | ($36.0K) | ($21.0K) | ($18.0K) |
| Net Income | ($42.76M) | ($47.91M) | ($29.07M) | ($29.15M) | ($33.94M) | ($32.76M) |
| EPS - Basic | ($0.32) | ($0.47) | ($0.29) | ($1.49) | - | - |
| EPS - Diluted | ($0.32) | ($0.47) | ($0.29) | ($1.49) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $18.91M | $34.10M | $32.40M | $12.59M | $36.83M | $45.00M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $3.91M | $3.41M | $1.81M | $2.86M | $2.85M | $2.02M |
| Current Assets | $191.66M | $109.43M | $87.55M | $122.62M | $37.96M | $46.27M |
| Total Assets | $193.44M | $110.90M | $89.40M | $123.02M | $38.48M | $47.13M |
| Current Liabilities | $9.75M | $10.51M | $5.82M | $13.40M | $12.72M | $5.55M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $10.20M | $11.26M | $6.86M | $15.56M | $21.40M | - |
| Stockholders' Equity | $183.24M | $99.64M | $82.55M | $107.46M | $17.07M | $27.28M |
| Retained Earnings | ($329.80M) | ($287.05M) | ($239.13M) | ($210.07M) | ($180.92M) | ($146.98M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($42.09M) | ($38.26M) | ($31.71M) | ($28.18M) | ($28.95M) | ($29.00M) |
| Investing Cash Flow | ($94.11M) | ($21.53M) | $59.43M | ($107.37M) | - | ($32.0K) |
| Financing Cash Flow | $121.01M | $61.48M | ($7.91M) | $111.31M | $20.77M | $16.72M |
| CapEx | $12.0K | $35.0K | $137.0K | $159.0K | - | $32.0K |
| Free Cash Flow | ($42.10M) | ($38.29M) | ($31.85M) | ($28.33M) | - | ($29.03M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.98 | 0.80 | 1.10 | 0.97 | - | 0.89 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -22.1% | -43.2% | -32.5% | -23.7% | -88.2% | -69.5% |
| Return on equity | -23.3% | -48.1% | -35.2% | -27.1% | -198.8% | -120.1% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 19.66 | 10.41 | 15.03 | 9.15 | 2.98 | 8.33 |
| Quick ratio | 19.66 | 10.41 | 15.03 | 9.15 | 2.98 | 8.33 |
| Cash ratio | 1.94 | 3.24 | 5.56 | 0.94 | 2.89 | 8.10 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | -12881.0x | -86.8x | -25.7x | -27.0x | -71.2x |
| Equity multiplier | 1.06 | 1.11 | 1.08 | 1.14 | 2.25 | 1.73 |
| Liabilities / Assets | 0.05 | 0.10 | 0.08 | 0.13 | 0.56 | - |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 9.2x | 4.2x | 1.6x | 0.4x | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 4.3% | -51.9% | -13.4% | 7.9% | 0.0% | -76.5% |
| Net income growth (YoY) | 10.8% | -64.8% | 0.3% | 14.1% | -3.6% | -25.8% |
| EPS growth (YoY) | 31.9% | -62.1% | 80.5% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -10.0% | -20.2% | -12.4% | - | - | -57.4% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 83.9% | 20.7% | -23.2% | 529.3% | -37.4% | -50.0% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Trevi Therapeutics against the 5 most active filers in the same SIC group.